Japan Trend Of Concurrent Trials Leads ICON To Triple Japan Staff
This article was originally published in PharmAsia News
Executive Summary
A Japan drug maker trend toward concurrent trials of drugs has led Ireland-based ICON to triple its Japanese workforce over the next three years